<DOC>
	<DOCNO>NCT02283450</DOCNO>
	<brief_summary>Purpose : Research impact Qiliqiangxin capsule IFN-γ，IL-4，NT-proBNP dilate cardiomyopathy patient heart failure . Methods : Data collect patient idiopathic dilate cardiomyopathy ( cardiac function NYHA Ⅱ-Ⅳ ) first affiliated hospital Harbin Medical University May 2012 April 2014 . These 30 case treated recommendation normal diagnosis treatment cardiomyopathy . This experiment randomize double-blinded，the experimental interference avoid patient divide experimental group placebo group . The patient experimental group receive relevant test inspection begin experiment，signed informed consent . Then investigator get venous blood centrifugalization cryopreservation . The patient take medicine qiliqiangxin three time per day，four tablet time . Afrer month，the investigator evaluate symptoms，the function heart，blood pressure，heart rate keep blood specimen . Three six month later，electrocardiogram echocardiography take determination NT - proBNP do . The placebo group follow way .</brief_summary>
	<brief_title>Regulation Immunological Cytokines Qiliqiangxin Capsule Dilated Cardiomyopathy Patients</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Cardiomyopathy , Dilated</mesh_term>
	<criteria>Congetive heart failure Valvular heart disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>